Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
about
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.Engineering chimeric antigen receptor-T cells for cancer treatment.Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.Current Strategies to Enhance Anti-Tumour Immunity.Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins.Tapping the RNA world for therapeutics.Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma.Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions.Cytokine release syndrome.Chimeric antigen receptor T‑cell therapy—a hematological success story.Cancer Immunotherapy in Diffuse Large B-Cell LymphomaDevelopment and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell VectorCAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple MyelomaManagement of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspectiveEnhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d TargetingOncolytic Viruses Partner With T-Cell Therapy for Solid Tumor TreatmentCharacterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy systemThe Potential of CAR T Cell Therapy in Pancreatic CancerCAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor ChallengeFrom scientific discovery to treatments for rare diseases - the view from the National Center for Advancing Translational Sciences - Office of Rare Diseases ResearchCurrent Immunotherapeutic Approaches in T Cell Non-Hodgkin LymphomasSurface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of LymphocytesAge-Related Chromosomal Aberrations in Patients with Diffuse Large B-Cell Lymphoma: An ApproachThe biological basis and clinical symptoms of CAR-T therapy-associated toxicitesThe Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of MelanomaNew developments in immunotherapy for lymphoma4-1BB enhancement of CAR T function requires NF-κB and TRAFs
P2860
Q49878390-6535D56C-262A-44CC-831D-EE736A7F1098Q49962991-ABE93E89-E317-491C-AA2A-9747CB70BBBAQ49999453-53B8371E-A971-4B02-8AA9-761EC1506B9DQ52344613-9FD9EDEE-7313-4868-A9F6-A62D5593F0DDQ52431261-777445A8-3BA7-4203-869C-4F3CAB021CCCQ52584544-2E7278D5-96DD-41BF-A76E-AD4235760C80Q52615722-FCD1CF67-5648-4F91-A3A2-D34AB2092219Q52721068-94DCC4B0-4E36-4F69-8F3A-F87635BE8F65Q54965277-1898447D-514B-4E58-A20A-7EC0147A72F9Q54979818-D1834886-03CC-488A-8D85-28DA0444E621Q55340132-1EB10D8C-24EF-4C28-A12F-ADD8F15B242EQ55419590-8DA3111E-FFC6-499D-B820-892807628ED5Q55438228-33BD1965-F25B-486C-8FD6-DD0C901C65D2Q55443158-0D2F606B-CB8E-4C83-99B2-8A12965C4DC6Q56889030-D8A5D3E4-7F78-493E-A6A2-285F6DAEBA52Q56889227-F0C1C37D-2037-46A6-9683-6E249A268D36Q56966447-D3D7E535-C2F5-410F-BC25-A1F32F0230ADQ57174502-9FD88D26-89A7-44D1-93C6-7954A0257DB5Q57293724-790AFF50-A37F-4EF9-9012-537DBA4D8D31Q57300017-051E0F9E-8252-46F9-8C3F-7DB37F6230FBQ57482923-B99864F3-85D7-4B76-A13C-6F725185F34BQ57492021-254069FF-667D-46A0-85D7-C4F74133AB8AQ58572502-D151DF63-56E2-4C90-A9B8-9F728FF95240Q58608362-63D8ECF2-6758-4CB8-9D23-94900D1E724CQ58723337-E5298CDF-CE84-476B-8719-9A1FC1856F15Q58726929-ECA309D0-CC1F-407A-BD7A-5BAC9B7217DEQ58761499-5F6FC482-45EB-4E9C-BD05-E2BF01981B5DQ58765358-41C2AF1D-1E75-4E27-BCB4-499044FA7384Q58788254-52D9F8EB-4191-4AF2-B4F2-8D3096C404E5Q58804962-88C2D430-3220-40B9-B8A5-3E887390DAF7Q59134955-32D00550-AB4D-417C-AF0A-DB02B6194939
P2860
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
@en
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
@nl
type
label
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
@en
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
@nl
prefLabel
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
@en
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
@nl
P2093
P2860
P50
P356
P1476
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
@en
P2093
Abhinav Deol
Adrian Bot
Armin Ghobadi
Brian T Hill
Caron A Jacobson
David B Miklos
David Chang
Eric D Jacobsen
Frederick L Locke
P2860
P304
P356
10.1056/NEJMOA1707447
P407
P577
2017-12-10T00:00:00Z